307 related articles for article (PubMed ID: 26880962)
1. The Progress of Induced Pluripotent Stem Cells as Models of Parkinson's Disease.
Kang JF; Tang BS; Guo JF
Stem Cells Int; 2016; 2016():4126214. PubMed ID: 26880962
[TBL] [Abstract][Full Text] [Related]
2. Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
Beevers JE; Caffrey TM; Wade-Martins R
Biochem Soc Trans; 2013 Dec; 41(6):1503-8. PubMed ID: 24256244
[TBL] [Abstract][Full Text] [Related]
3. Modeling Parkinson's Disease Using Induced Pluripotent Stem Cells.
Hu X; Mao C; Fan L; Luo H; Hu Z; Zhang S; Yang Z; Zheng H; Sun H; Fan Y; Yang J; Shi C; Xu Y
Stem Cells Int; 2020; 2020():1061470. PubMed ID: 32256606
[TBL] [Abstract][Full Text] [Related]
4. What we can learn from iPSC-derived cellular models of Parkinson's disease.
Caiazza MC; Lang C; Wade-Martins R
Prog Brain Res; 2020; 252():3-25. PubMed ID: 32247368
[TBL] [Abstract][Full Text] [Related]
5. Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.
Li H; Jiang H; Zhang B; Feng J
J Parkinsons Dis; 2018; 8(4):479-493. PubMed ID: 30149462
[TBL] [Abstract][Full Text] [Related]
6. Cellular reprogramming: a new approach to modelling Parkinson's disease.
Hartfield EM; Fernandes HJ; Vowles J; Cowley SA; Wade-Martins R
Biochem Soc Trans; 2012 Oct; 40(5):1152-7. PubMed ID: 22988881
[TBL] [Abstract][Full Text] [Related]
7. Using iPS Cells toward the Understanding of Parkinson's Disease.
Torrent R; De Angelis Rigotti F; Dell'Era P; Memo M; Raya A; Consiglio A
J Clin Med; 2015 Mar; 4(4):548-66. PubMed ID: 26239346
[TBL] [Abstract][Full Text] [Related]
8. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
[TBL] [Abstract][Full Text] [Related]
9. Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.
Sison SL; Vermilyea SC; Emborg ME; Ebert AD
Curr Neurol Neurosci Rep; 2018 Oct; 18(12):84. PubMed ID: 30284665
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.
Cooper O; Seo H; Andrabi S; Guardia-Laguarta C; Graziotto J; Sundberg M; McLean JR; Carrillo-Reid L; Xie Z; Osborn T; Hargus G; Deleidi M; Lawson T; Bogetofte H; Perez-Torres E; Clark L; Moskowitz C; Mazzulli J; Chen L; Volpicelli-Daley L; Romero N; Jiang H; Uitti RJ; Huang Z; Opala G; Scarffe LA; Dawson VL; Klein C; Feng J; Ross OA; Trojanowski JQ; Lee VM; Marder K; Surmeier DJ; Wszolek ZK; Przedborski S; Krainc D; Dawson TM; Isacson O
Sci Transl Med; 2012 Jul; 4(141):141ra90. PubMed ID: 22764206
[TBL] [Abstract][Full Text] [Related]
11. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells.
Stoddard-Bennett T; Reijo Pera R
Cells; 2019 Jan; 8(1):. PubMed ID: 30621042
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 impairs PINK1/Parkin-dependent mitophagy via its kinase activity: pathologic insights into Parkinson's disease.
Bonello F; Hassoun SM; Mouton-Liger F; Shin YS; Muscat A; Tesson C; Lesage S; Beart PM; Brice A; Krupp J; Corvol JC; Corti O
Hum Mol Genet; 2019 May; 28(10):1645-1660. PubMed ID: 30629163
[TBL] [Abstract][Full Text] [Related]
14. Targeting α-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models.
Spathopoulou A; Edenhofer F; Fellner L
Front Neurol; 2021; 12():786835. PubMed ID: 35145469
[TBL] [Abstract][Full Text] [Related]
15. Generation of induced pluripotent stem cell line (ZZUi007-A) from a 52-year-old patient with a novel CHCHD2 gene mutation in Parkinson's disease.
Wang Y; Wang Z; Sun H; Mao C; Yang J; Liu Y; Liu H; Zhang S; Zhang J; Xu Y; Shi C
Stem Cell Res; 2018 Oct; 32():87-90. PubMed ID: 30237140
[TBL] [Abstract][Full Text] [Related]
16. Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling.
Hu Z; Pu J; Jiang H; Zhong P; Qiu J; Li F; Wang X; Zhang B; Yan Z; Feng J
Stem Cells Dev; 2015 Nov; 24(21):2591-604. PubMed ID: 26218671
[TBL] [Abstract][Full Text] [Related]
17. Using induced pluripotent stem cells for modeling Parkinson's disease.
Ke M; Chong CM; Su H
World J Stem Cells; 2019 Sep; 11(9):634-649. PubMed ID: 31616540
[TBL] [Abstract][Full Text] [Related]
18. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
19. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
20. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
